SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value theranostic intellectual property, we are poised to deliver on the promise of radiopharmaceuticals from start to clinic. www.sofie.com www.twitter.com/sofiebio www.instagram.com/sofiebio
Location: United States, California, Culver City
Employees: 201-500
Total raised: $27.4M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Cycad Grou... | cycadvc.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.11.2020 | Series C | $27.4M | - |
Mentions in press and media 2
| Date | Title | Description |
| 05.06.2024 | SOFIE Biosciences Receives Strategic Growth Investment from Trilantic North America | SOFIE Biosciences, a Dulles, VA-based radiopharmacy and contract development and manufacturing organization, received a strategic growth investment from Trilantic North America. The amount of the deal was not disclosed. The investment was m... |
| 31.01.2024 | Trilantic North America Makes Strategic Growth Investment in SOFIE Biosciences | Trilantic North America announced today that it has entered into a definitive agreement to make a substantial growth investment in SOFIE Biosciences (“SOFIE” or the “Company”), a Positron Emission Tomography (“PET”) radiopharmacy and contra... |